

Medicine	Indication	Further Information	Type	LSCMMG planned
ITULAZAX 12 SQ-Bet sublingual lyophilisate	Treatment of moderate-to-severe allergic rhinitis induced by pollen from the birch homologous group	Requested by Consultant ENT Lancashire Teaching Hospitals NHS Foundation Trust	Major	Uncertain – NICE due September 2025
Diclofenac oral	Initiation of treatment by Rheumatologists	Currently Green (restricted) for short term treatment of post-op pain, renal colic and lithotripsy only	Moderate	March 2025
Drospirenone	Contraception	Raised at NW Medicines Management collaborative meeting. Product included in national PGD	Major	April 2025
Bismuth potassium with metronidazole and tetracycline hydrochloride	In combination with omeprazole, for the eradication of Helicobacter pylori and prevention of relapse of peptic ulcers in patients with active or a history of H. pylori associated ulcers.	Supported by SMC, prioritised at December 2024 LSCMMG	Moderate	April 2025

Medicines for prioritisation				
Actimorph	Treatment of pain, non-palliative patients	Requested by Morecambe Bay ICB locality		Major
Fezolinetant (Veozah®)	Hot flushes in those unable to take HRT	Requested by Fylde Coast ICB locality. Under review by NICE, anticipated publication 21 May 2025		Major
Dienogest	Endometriosis	Requested by FWG		Major
Budenofalk suppositories	Short-term treatment of mild to moderate acute ulcerative colitis limited to the rectum (ulcerative proctitis) in adult patients	Requested by Gastroenterology ELHT		Major/moderate
Cinacalcet	Request to review Red RAG rating to allow supply in community	Requested by FWG		Major

Botulinum toxin	Treatment of anal fissure	Requested by FWG	Major/moderate
Fatty acid enema	Diversion Colitis	Requested by FWG, previously approved by ELMMB	Major/moderate